A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment

Abstract : CMT1A is the most common inherited peripheral neuropathy. There is currently no approved treatment. We performed a meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression after one year under Placebo, Ascorbic Acid (AA) or PXT3003, a combination of three repurposed drugs. We observed a weak deterioration in patients under Placebo, well below the reported natural disease progression. Patients treated with AA were stable after one year but not significantly different from Placebo. Patients undergoing PXT3003 treatment showed an improvement in CMTNS and ONLS, statistically significant versus Placebo and potentially precursory of a meaningful change in the disease course.
Complete list of metadatas

Cited literature [23 references]  Display  Hide  Download

https://hal-amu.archives-ouvertes.fr/hal-01203428
Contributor : Administrateur Hal Amu <>
Submitted on : Wednesday, September 23, 2015 - 9:30:04 AM
Last modification on : Monday, August 27, 2018 - 9:44:38 AM
Long-term archiving on : Tuesday, December 29, 2015 - 9:28:58 AM

File

s13023-015-0293-y.pdf
Publisher files allowed on an open archive

Identifiers

  • HAL Id : hal-01203428, version 1

Collections

Citation

Jonas Mandel, Viviane Bertrand, Philippe Lehert, Shahram Attarian, Laurent Magy, et al.. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Orphanet Journal of Rare Diseases, BioMed Central, 2015. ⟨hal-01203428⟩

Share

Metrics

Record views

192

Files downloads

201